These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26108574)

  • 1. The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development.
    Awwad S; Lockwood A; Brocchini S; Khaw PT
    J Pharm Sci; 2015 Oct; 104(10):3330-42. PubMed ID: 26108574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye.
    Awwad S; Day RM; Khaw PT; Brocchini S; Fadda HM
    Int J Pharm; 2017 Apr; 522(1-2):119-127. PubMed ID: 28232270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
    Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
    Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
    Kamppeter BA; Cej A; Jonas JB
    Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
    Chen M; Li X; Liu J; Han Y; Cheng L
    J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
    Beer PM; Bakri SJ; Singh RJ; Liu W; Peters GB; Miller M
    Ophthalmology; 2003 Apr; 110(4):681-6. PubMed ID: 12689886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide.
    Sabzevari A; Adibkia K; Hashemi H; De Geest BG; Mohsenzadeh N; Atyabi F; Ghahremani MH; Khoshayand MR; Dinarvand R
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5520-6. PubMed ID: 23833065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration.
    Zarei-Ghanavati S; Malaekeh-Nikouei B; Pourmazar R; Seyedi S
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):502-6. PubMed ID: 22537291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different intravitreal properties of three triamcinolone formulations and their possible impact on retina practice.
    Chen H; Sun S; Li J; Du W; Zhao C; Hou J; Xu Y; Cheng L
    Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2178-85. PubMed ID: 23449717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
    Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of rituximab following an intravitreal injection.
    Kim H; Csaky KG; Chan CC; Bungay PM; Lutz RJ; Dedrick RL; Yuan P; Rosenberg J; Grillo-Lopez AJ; Wilson WH; Robinson MR
    Exp Eye Res; 2006 May; 82(5):760-6. PubMed ID: 16289160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
    Daull P; Paterson CA; Kuppermann BD; Garrigue JS
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide.
    Kuo CH; McCluskey P; Gillies M
    Expert Opin Pharmacother; 2010 Jan; 11(1):155-66. PubMed ID: 20001437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular availability of triamcinolone acetonide after intravitreal injection.
    Jonas JB
    Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
    Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection.
    Cheng L; Banker AS; Martin M; Kozak I; Freeman WR
    Ophthalmology; 2009 Jul; 116(7):1356-9. PubMed ID: 19450879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
    Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.
    Shen L; You Y; Sun S; Chen Y; Qu J; Cheng L
    Ophthalmology; 2010 Dec; 117(12):2365-71. PubMed ID: 20678801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.